A few months ago I posted in the original message in this thread wondering if a BETonMACE rationale, design and baseline data publication might be in the works (typical of major cardiovascular outcomes trials). Back on the April 18, 2019 news release about hitting 250 events and the 2-4 months estimate for top-line date, I emailed IR and asked "Is Resverlogix and/or the BETonMACE clinical steering committee planning to publish a BETonMACE study rationale and design paper in advance of the top-line data announcement?" IR responded that same day "Yes, the goal is to publish a design paper prior to top line read-out. More information to come in due course." If publishing this paper in advance of top-line is still the plan, then one would think we should see it very soon. Tick tock.

BearDownAZ